Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia

By afschroeder • March 21, 2026

Rugo HS, Tolaney SM, Cortés J, Marmé F, de Azambuja E, Xu B, Sohn J, Naito Y, Valdez T, Gary D, Zhu J, Lai C, Bardia A. Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia. ESMO Open. 2026 Mar 19;11(4):106905. doi: 10.1016/j.esmoop.2026.106905. Epub ahead of print. PMID: 41861751.

Tags: Hematology/Oncology, HR-positive/HER2-negative metastatic breast cancer, metastatic triple-negative breast cancer, Pooled analysis, Publications, Sacituzumab govitecan, safety

Related Posts

Overcoming T cell tolerance to tumor self-antigens through catch-bond engineering

Chen X, Mao Z, Kolawole EM, Persechino M, Jude KM, Ogishi M, Mo KC, McLaughlin J, Cheng D, Xiang X, Yang X, Gee C, Liu[...]

A phase II randomized placebo-controlled study of fisetin to improve physical function in breast cancer survivors: the TROFFi study rationale and trial design

Ji J, Crespi CM, Yee L, Zekster YA, Al-Saleem A, Petersen L, Lee C, Son N, Smith C, Evans T, Tchkonia T, Kirkland JL, Kuchel[...]

First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies

Razak A, Mahipal A, Diamond JR, Ribas A, Berlin JD, Azmi AS, Mark T, Walker CJ, Chai Y, Kashyap T, Gudi G, Naing A. First-in-Human[...]